ECCO 2024-话题@MedSci - 梅斯（MedSci）

#ECCO 2024#

0篇内容 | 859人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189296, encodeId=fd702189296bc, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a> <a href='/topic/show?id=dded1115324c' target=_blank style='color:#2F92EE;'>#中重度活动性溃疡性结肠炎#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量, objectType=article, longId=814760, objectId=f144814e609a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708857943062_8624274.png, objectUrl=/article/show_article.do?id=f144814e609a, replyNumber=0, likeNumber=115, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f144814e609a, moduleTitle=ECCO 2024：Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f144814e609a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189298, encodeId=50db2189298c7, content=<a href='/topic/show?id=05c46645ec3' target=_blank style='color:#2F92EE;'>#溃疡性结肠炎#</a> <a href='/topic/show?id=b92d233416b' target=_blank style='color:#2F92EE;'>#乌司奴单抗#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：乌司奴单抗治疗溃疡性结肠炎的短期和长期有效性与安全性：ULISES 研究, objectType=article, longId=814758, objectId=83a4814e581e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708856569560_8624274.png, objectUrl=/article/show_article.do?id=83a4814e581e, replyNumber=0, likeNumber=107, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=83a4814e581e, moduleTitle=ECCO 2024：乌司奴单抗治疗溃疡性结肠炎的短期和长期有效性与安全性：ULISES 研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=83a4814e581e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189349, encodeId=b3502189349e0, content=<a href='/topic/show?id=aa55894226c' target=_blank style='color:#2F92EE;'>#血清生物标志物#</a> <a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎症性肠病#</a> <a href='/topic/show?id=848de9023d1' target=_blank style='color:#2F92EE;'>#维多珠单抗#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：维多珠单抗治疗炎症性肠病相关的血清生物标志物评估, objectType=article, longId=814763, objectId=fada814e6395, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708860973947_8624274.png, objectUrl=/article/show_article.do?id=fada814e6395, replyNumber=0, likeNumber=89, createdTime=2024-02-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fada814e6395, moduleTitle=ECCO 2024：维多珠单抗治疗炎症性肠病相关的血清生物标志物评估, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fada814e6395)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189242, encodeId=f59f2189242b0, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a> <a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性, objectType=article, longId=814628, objectId=7995814628eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708780755122_8624274.png, objectUrl=/article/show_article.do?id=7995814628eb, replyNumber=0, likeNumber=75, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7995814628eb, moduleTitle=ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7995814628eb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189162, encodeId=1c8c21891628a, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=4a291193275' target=_blank style='color:#2F92EE;'>#Mirikizumab#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Mirikizumab治疗中重度克罗恩病的初步疗效和安全性：VIVID 1研究结果, objectType=article, longId=814624, objectId=128e8146248a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708777352045_8624274.png, objectUrl=/article/show_article.do?id=128e8146248a, replyNumber=0, likeNumber=87, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=128e8146248a, moduleTitle=ECCO 2024：Mirikizumab治疗中重度克罗恩病的初步疗效和安全性：VIVID 1研究结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=128e8146248a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189166, encodeId=9beb21891663b, content=<a href='/topic/show?id=b92d233416b' target=_blank style='color:#2F92EE;'>#乌司奴单抗#</a> <a href='/topic/show?id=4a291193275' target=_blank style='color:#2F92EE;'>#Mirikizumab#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Mirikizumab与乌司奴单抗对中重度克罗恩病患者的疗效比较, objectType=article, longId=814619, objectId=5e32814619ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708774713658_8624274.png, objectUrl=/article/show_article.do?id=5e32814619ad, replyNumber=0, likeNumber=89, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5e32814619ad, moduleTitle=ECCO 2024：Mirikizumab与乌司奴单抗对中重度克罗恩病患者的疗效比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5e32814619ad)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189168, encodeId=bf1f218916842, content=<a href='/topic/show?id=4a291193275' target=_blank style='color:#2F92EE;'>#Mirikizumab#</a> <a href='/topic/show?id=e80265168c3' target=_blank style='color:#2F92EE;'>#活动性克罗恩病#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Mirikizumab可改善中度至重度活动性克罗恩病患者的疲劳、排便紧迫感和生活质量：一项三期临床试验, objectType=article, longId=814618, objectId=5f148146186c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708769285437_8624274.png, objectUrl=/article/show_article.do?id=5f148146186c, replyNumber=0, likeNumber=91, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5f148146186c, moduleTitle=ECCO 2024：Mirikizumab可改善中度至重度活动性克罗恩病患者的疲劳、排便紧迫感和生活质量：一项三期临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5f148146186c)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

克罗恩病 Mirikizumab ECCO 2024

2024-02-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#Guselkumab# #中重度活动性溃疡性结肠炎# #ECCO 2024#

ECCO 2024：Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量

2024-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#溃疡性结肠炎# #乌司奴单抗# #ECCO 2024#

ECCO 2024：乌司奴单抗治疗溃疡性结肠炎的短期和长期有效性与安全性：ULISES 研究

2024-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#血清生物标志物# #炎症性肠病# #维多珠单抗# #ECCO 2024#

ECCO 2024：维多珠单抗治疗炎症性肠病相关的血清生物标志物评估

2024-02-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#risankizumab# #活动性溃疡性结肠炎# #ECCO 2024#

ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性

2024-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #Mirikizumab# #ECCO 2024#

ECCO 2024：Mirikizumab治疗中重度克罗恩病的初步疗效和安全性：VIVID 1研究结果

2024-02-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乌司奴单抗# #Mirikizumab# #ECCO 2024#

ECCO 2024：Mirikizumab与乌司奴单抗对中重度克罗恩病患者的疗效比较

2024-02-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#Mirikizumab# #活动性克罗恩病# #ECCO 2024#

ECCO 2024：Mirikizumab可改善中度至重度活动性克罗恩病患者的疲劳、排便紧迫感和生活质量：一项三期临床试验

2024-02-24发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务